{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064475","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.948374+00:00","generated_at":"2026-05-22T11:11:17.496618+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"confidence":"high","headline":"Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025","bullets":["Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.","Cash & equivalents $31.7M at March 31, 2025, down from $40.6M at Dec 31, 2024.","Topline Phase 3 ENLIGHTEN 2 data for LYR-210 in CRS expected in Q2 2025; ~65 polyp patients across both ENLIGHTEN trials.","Plans a reverse stock split to comply with Nasdaq $1.00 minimum bid; stockholder vote on May 14, 2025.","R&D expenses fell to $4.9M from $18.2M YoY, driven by completion of BEACON and ENLIGHTEN 1 trials and May 2024 workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064475","json":"https://secwatch.observer/filing/0000950170-25-064475.json","markdown":"https://secwatch.observer/filing/0000950170-25-064475.md","text":"https://secwatch.observer/filing/0000950170-25-064475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/0000950170-25-064475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/lyra-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:11:17.496618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}